2. Academic Validation
  3. p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas

p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas

  • Bioorg Med Chem Lett. 2001 Jan 8;11(1):9-12. doi: 10.1016/s0960-894x(00)00574-6.
A M Redman 1,  J S Johnson,  R Dally,  S Swartz,  H Wild,  H Paulsen,  Y Caringal,  D Gunn,  J Renick,  M Osterhout,  J Kingery-Wood,  R A Smith,  W Lee,  J Dumas,  S M Wilhelm,  T J Housley,  A Bhargava,  G E Ranges,  A Shrikhande,  D Young,  M Bombara,  W J Scott
Affiliations

Affiliation

  • 1 Department of Chemistry Research, Bayer Research Center, Pharmaceutical Division, West Haven, CT 06516, USA. aniko.redman.b@bayer.com
PMID: 11140741 DOI: 10.1016/s0960-894x(00)00574-6
Abstract

Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and Other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z